苯环喹溴铵联合左西替利嗪治疗中重度变应性鼻炎的疗效及其对患者血清炎症因子的影响

Efficacy of bencycloquidium bromide combined with levocetirizine in the treatment of moderate to severe allergic rhinitis and its impact on serum inflammatory factors

摘要:

目的 探讨苯环喹溴铵联合左西替利嗪治疗中重度变应性鼻炎(AR)的疗效以及对炎症因子的影响。方法 选取持续性中重度AR患者100例，随机将其分为单药组(n=50)和联合组(n=50)。单药组给予左西替利嗪口服；联合组在口服左西替利嗪的基础上，给予苯环喹溴铵鼻吸入剂治疗，两组均治疗4周。比较两组治疗前和治疗2、4周的视觉模拟量表(VAS)评分，同时收集患者静脉血，检测治疗前和治疗4周后的血清炎症因子[白细胞介素(IL)-1β、IL-4、IL-6]水平，同时记录不良反应。结果 治疗前，单药组和联合组的VAS评分、血清炎症因子水平差异无统计学意义(P＞0.05)。与治疗前比较，治疗后两组的VAS评分、血清炎症因子水平均降低；治疗2周后，联合组的VAS评分、喷嚏、鼻痒、鼻涕评分低于单药组，差异具有统计学意义(P＜0.05)；治疗4周后，联合组的VAS评分、喷嚏、鼻痒、鼻涕、鼻塞评分以及血清炎症因子(IL-1β、IL-4、IL-6)水平均低于单药组，差异具有统计学意义(P＜0.05)。两组治疗期间均未发生严重不良反应事件。结论 苯环喹溴铵联合左西替利嗪治疗中重度AR比单用左西替利嗪有效，且不增加不良反应。

Abstract:

Objective To explore the effect of bencycloquidium bromide combined with levocetirizine in the treatment of moderate to severe allergic rhinitis (AR) and its impact on inflammatory factors.Methods A total of 100 patients with persistent moderate to severe AR were selected and randomly divided into monotherapy group (n=50) and combination group (n=50). The monotherapy group was given levocetirizine orally, while the combination group was treated with bencycloquidium bromide nasal inhalant on the basis of oral levocetirizine. Both groups were treated for 4 weeks. Visual analog scale (VAS) scores between the two groups before treatment and at 2 and 4 weeks of treatment were compared, and venous blood was collected to detect serum inflammatory factor [interleukin(IL)-1β, IL-4, IL-6] levels before treatment and 4 weeks of treatment, and adverse reactions were recorded.Results Before treatment, there were no statistically significant differences in VAS scores and serum inflammatory factor levels between the monotherapy group and the combination group (P>0.05). Compared with before treatment, the VAS scores and serum inflammatory factor levels in both groups decreased after treatment. After 2 weeks of treatment, the VAS score, sneezing, itching, and rhinirrhea scores of the combination group were lower than those of the monotherapy group, and the differences were statistically significant (P<0.05). After 4 weeks of treatment, the VAS score, sneezing, itching, rhinirrhea, congestion scores, and serum inflammatory factor (IL-1β, IL-4, IL-6) levels in the combination group were lower than those in the monotherapy group, and the differences were statistically significant (P<0.05). No serious adverse reactions occurred in both groups during treatment.Conclusion The combination of bencycloquidium bromide and levocetirizine is more effective in treating moderate to severe AR than levocetirizine alone, without increasing adverse reactions.